{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:39:56Z","timestamp":1763105996583},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,21]]},"DOI":"10.7759\/cureus.56622","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:13:39Z","timestamp":1711019619000},"source":"Crossref","is-referenced-by-count":2,"title":["Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease"],"prefix":"10.7759","author":[{"given":"Toyoshi","family":"Yanagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atushi","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots DR","year":"2015","unstructured":"Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015, 36:13-34. 10.1016\/j.ccm.2014.10.002","journal-title":"Clin Chest Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel R","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, Loddenkemper R. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018, 153:888-921. 10.1016\/j.chest.2018.01.024","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak N","year":"2017","unstructured":"Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017, 65:1077-84. 10.1093\/cid\/cix517","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers P","year":"2008","unstructured":"Meers P, Neville M, Malinin V, et al.. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008, 61:859-68. 10.1093\/jac\/dkn059","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang J","year":"2018","unstructured":"Zhang J, Leifer F, Rose S, et al.. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018, 9:915. 10.3389\/fmicb.2018.00915","journal-title":"Front Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier KN","year":"2017","unstructured":"Olivier KN, Griffith DE, Eagle G, et al.. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017, 195:814-23. 10.1164\/rccm.201604-0700OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (convert). A prospective, open-label, randomized study","volume":"198","author":"Griffith DE","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al.. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (convert). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018, 198:1559-69. 10.1164\/rccm.201807-1318OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley CL","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al.. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020, 71:e1-e36. 10.1093\/cid\/ciaa241","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith DE","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007, 175:367-416. 10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2023.0120","article-title":"Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease","author":"Kim BG","year":"2023","unstructured":"Kim BG, Kim SR, Jhun BW. Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease. Tuberc Respir Dis (Seoul). 2023, 10.4046\/trd.2023.0120","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2023.12.012","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: a subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study","volume":"62","author":"Morimoto K","year":"2024","unstructured":"Morimoto K, Nonaka M, Yamazaki Y, et al.. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: a subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study. Respir Investig. 2024, 62:284-90. 10.1016\/j.resinv.2023.12.012","journal-title":"Respir Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop KL","year":"2021","unstructured":"Winthrop KL, Flume PA, Thomson R, et al.. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial. Ann Am Thorac Soc. 2021, 18:1147-57. 10.1513\/AnnalsATS.202008-925OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref13","article-title":"An incidence of the ethambutol-induced optic neuropathy and the usefulness of a periodic visual acuity test: a questionnaire survey in Japan","volume":"2","author":"Masataka M","year":"2013","unstructured":"Masataka M, Masamitsu H, Toshiyasu S, et al.. An incidence of the ethambutol-induced optic neuropathy and the usefulness of a periodic visual acuity test: a questionnaire survey in Japan. Ann Japanese Respir Soc. 2013, 2:187-92.","journal-title":"Ann Japanese Respir Soc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto K","year":"2016","unstructured":"Morimoto K, Namkoong H, Hasegawa N, et al.. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016, 13:1904-11. 10.1513\/AnnalsATS.201604-246OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/srep29325","article-title":"Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis","volume":"6","author":"Shibata Y","year":"2016","unstructured":"Shibata Y, Horita N, Yamamoto M, et al.. Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis. Sci Rep. 2016, 6:29325. 10.1038\/srep29325","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106585","article-title":"Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment","volume":"187","author":"Fukushima K","year":"2021","unstructured":"Fukushima K, Kitada S, Matsumoto Y, et al.. Serum GPL core antibody levels are associated with disease activity and treatment outcomes in Mycobacterium avium complex lung disease following first line antibiotic treatment. Respir Med. 2021, 187:106585. 10.1016\/j.rmed.2021.106585","journal-title":"Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06182-9","article-title":"Association of serum antibodies against the Mycobacterium avium complex and hemoptysis: a cross-sectional study","volume":"21","author":"Ogata H","year":"2021","unstructured":"Ogata H, Moriwaki A, Nakagawa T, et al.. Association of serum antibodies against the Mycobacterium avium complex and hemoptysis: a cross-sectional study. BMC Infect Dis. 2021, 21:480. 10.1186\/s12879-021-06182-9","journal-title":"BMC Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/237135-amikacin-liposome-inhalation-suspension-in-the-real-world-management-of-refractory-mycobacterium-avium-complex-pulmonary-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:13:44Z","timestamp":1711019624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/237135-amikacin-liposome-inhalation-suspension-in-the-real-world-management-of-refractory-mycobacterium-avium-complex-pulmonary-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.56622","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}